254 related articles for article (PubMed ID: 37543576)
1. Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.
Li J; Guo Q; Xing R
BMC Cancer; 2023 Aug; 23(1):727. PubMed ID: 37543576
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatics analyses and experimental validation of the role of phagocytosis in low-grade glioma.
Fei M; Lu C; Feng B; Sun J; Wang J; Sun F; Dong B
Environ Toxicol; 2024 Apr; 39(4):2182-2196. PubMed ID: 38112449
[TBL] [Abstract][Full Text] [Related]
3. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
Li Y; Feng Y; Luo F; Peng G; Li Y
Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
[TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
[No Abstract] [Full Text] [Related]
5. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.
Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y
Front Immunol; 2023; 14():1102094. PubMed ID: 37153540
[TBL] [Abstract][Full Text] [Related]
6. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
7. Predictive Panel for Immunotherapy in Low-Grade Glioma.
Lv Q; Zhang Z; Fu H; Li D; Liu Y; Sun Y; Wu M
World Neurosurg; 2024 Mar; 183():e825-e837. PubMed ID: 38216032
[TBL] [Abstract][Full Text] [Related]
8. Construction of a novel molecular typing and scoring system for anoikis distinguishes between different prognostic risks and treatment responsiveness in low-grade glioma.
Zhang G; Chen A; Fang J; Wu A; Chen G; Tai P; Chen H; Chen X; Cao K
Front Immunol; 2023; 14():1105210. PubMed ID: 37114037
[TBL] [Abstract][Full Text] [Related]
9. Multi-Omics Data Integration Analysis of an Immune-Related Gene Signature in LGG Patients With Epilepsy.
Cheng Q; Duan W; He S; Li C; Cao H; Liu K; Ye W; Yuan B; Xia Z
Front Cell Dev Biol; 2021; 9():686909. PubMed ID: 34336837
[TBL] [Abstract][Full Text] [Related]
10. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
Lin WW; Ou GY; Zhao WJ
J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
[TBL] [Abstract][Full Text] [Related]
11. A Whole Exon Screening-Based Score Model Predicts Prognosis and Immune Checkpoint Inhibitor Therapy Effects in Low-Grade Glioma.
Luo C; Wang S; Shan W; Liao W; Zhang S; Wang Y; Xin Q; Yang T; Hu S; Xie W; Xu N; Zhang Y
Front Immunol; 2022; 13():909189. PubMed ID: 35769464
[TBL] [Abstract][Full Text] [Related]
12. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma.
Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J
Front Immunol; 2023; 14():1220100. PubMed ID: 37662954
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
Front Immunol; 2022; 13():933973. PubMed ID: 36045691
[TBL] [Abstract][Full Text] [Related]
14. Establishment of three heterogeneous subtypes and a risk model of low-grade gliomas based on cell senescence-related genes.
Chen J; Wu L; Yang H; Zhang X; Xv S; Qian Q
Front Immunol; 2022; 13():982033. PubMed ID: 36052073
[TBL] [Abstract][Full Text] [Related]
15. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
16. Cuprotosis clusters predict prognosis and immunotherapy response in low-grade glioma.
Zhu W; Chen Z; Fu M; Li Q; Chen X; Li X; Luo N; Tang W; Yang F; Zhang Y; Zhang Y; Peng X; Hu G
Apoptosis; 2024 Feb; 29(1-2):169-190. PubMed ID: 37713112
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
Xu S; Tang L; Liu Z; Luo C; Cheng Q
Front Immunol; 2021; 12():731048. PubMed ID: 34659218
[TBL] [Abstract][Full Text] [Related]
18. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
19. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
[TBL] [Abstract][Full Text] [Related]
20. Association of RNA-modification "writer" genes with prognosis and response to immunotherapy in patients with low-grade glioma.
Zhang L; Qu C; Shi C; Wu F; Tang Y; Li Y; Li J; Feng H; Zhong S; Yang J; Zeng X; Peng X
PLoS One; 2023; 18(1):e0279119. PubMed ID: 36649311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]